Novartis provides update on Phase III GCAptAIN study of Cosentyx® in giant cell arteritis (GCA)PRNewsWire • 07/03/25
Buy These 5 Low-Leverage Stocks Amid Wall Street's Tricky July StartZacks Investment Research • 07/02/25
ProFound Therapeutics Announces Multi-Year Strategic Collaboration with Novartis to Discover and Develop Novel Therapeutics for Cardiovascular DiseaseGlobeNewsWire • 06/26/25
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood DisorderBenzinga • 06/12/25
Novartis Fabhalta® shows statistically significant and clinically meaningful improvements in hemoglobin in new population of patients with PNHGlobeNewsWire • 06/12/25
Novartis Pluvicto™ demonstrates statistically significant and clinically meaningful rPFS benefit in patients with PSMA-positive metastatic hormone-sensitive prostate cancerGlobeNewsWire • 06/02/25
Novartis announces commencement of tender offer to acquire Regulus TherapeuticsGlobeNewsWire • 05/27/25
New Novartis data at ASCO and EHA showcase momentum of pioneering portfolio with promising pipelineGlobeNewsWire • 05/15/25
Trump wants to slash U.S. drug prices with 'most favored nation' policy – here's what to knowCNBC • 05/12/25
Trump Declares War On Pharma Drug Pricing, But The Stocks Aren't Tanking - YetSeeking Alpha • 05/12/25